SCHEMBL2968874

SCHEMBL2968874

CC(C)(C)OC(=O)Nc1c(F)cccc1C=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.42
NLRP3 Q96P20 1/20 0.42
ATR Q13535 1/20 0.41
SYK P43405 1/20 0.39
ALDH1A1 P00352 2/20 0.38
LCK P06239 3/20 0.38
RXFP1 Q9HBX9 1/20 0.37
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
BACE1 P56817 1/20 0.36
CYP17A1 P05093 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954566 1.00 ERN1 (0.42) ERN1NLRP3ATRSYKALDH1A1
SCHEMBL1610508 0.86 NLRP3 (0.53) NLRP3ATRSYKALDH1A1LCK
SCHEMBL29957958 0.84 LCK (0.49) NLRP3ATRALDH1A1LCK
SCHEMBL4071542 0.83 LMNA (0.49) ATRLCKRXFP1LMNAPOLB
SCHEMBL29953468 0.83 LMNA (0.49) ATRLCKRXFP1LMNAPOLB
SCHEMBL29954888 0.83 LCK (0.49) NLRP3ATRALDH1A1LCKLMNA
SCHEMBL29954491 0.82 TLR2 (0.49) ERN1ATRALDH1A1LMNAPOLB
SCHEMBL2198998 0.82 TLR2 (0.49) ERN1ATRALDH1A1LMNAPOLB
SCHEMBL29956316 0.81 NLRP3 (0.43) NLRP3ATRSYKALDH1A1LCK
SCHEMBL1006953 0.81 NLRP3 (0.43) NLRP3ATRSYKALDH1A1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772244-B2 Therapeutic agents for the treatment of migraine BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-10 US disclosed
US-7772244-B2 Therapeutic agents for the treatment of migraine BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-10 US disclosed
US-7772244-B2 Therapeutic agents for the treatment of migraine BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-10 US disclosed
EP-1730137-A1 HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE Bristol-Myers Squibb Company (US) 2006-12-13 EP disclosed
WO-2005095383-A1 HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-13 WO disclosed
US-20050215576-A1 Novel therapeutic agents for the treatment of migraine BRISTOL-MYERS SQUIBB COMPANY 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215576-A1 Novel therapeutic agents for the treatment of migraine CALCRL, CALCR, CALCA ERN1 4421/4885NLRP3 421/4885ATR 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.